» Articles » PMID: 29601147

Supervised Physical Exercise Improves Clinical, Anthropometric and Biochemical Parameters in Adult Cystic Fibrosis Patients: A 2-year Evaluation

Overview
Journal Clin Respir J
Specialty Pulmonary Medicine
Date 2018 Mar 31
PMID 29601147
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Cystic fibrosis (CF) is the most common inherited, life limiting condition among Caucasians. No healing therapy is currently available for patients with CF. The aim of the study was to define clinical, anthropometric and biochemical effects of regular, supervised physical exercise in a large cohort of patients with CF.

Materials And Methods: Fifty-nine adult patients with CF that performed regularly supervised physical exercise in the last 3 years in comparison to 59 sex and age matched sedentary patients with CF were included in the study.

Results: Physical exercise had significantly beneficial effects on: (a) FEV1% decline; (b) anthropometric parameters (lower number of cases with altered BMI, waist and arm circumferences); (c) lipid and glucose metabolism; (d) vitamin D serum levels. Of course, some of this improvement may be because of the better adherence to therapy typical of patients with CF that perform physical activity.

Conclusions: Such clinical and metabolic effects make supervised physical activity one of the hubs in managing patients with CF.

Citing Articles

Liver biochemical indexes and cholesterol metabolism in cystic fibrosis patients with F508del/CFTR variant genotype after elexacaftor/tezacaftor/ivacaftor treatment.

Castaldo A, Iacotucci P, Bagnasco S, Fevola C, Carnovale V, Antonelli F Sci Rep. 2024; 14(1):17422.

PMID: 39075279 PMC: 11286749. DOI: 10.1038/s41598-024-68511-7.


Physical activity and its correlates in people with cystic fibrosis: a systematic review.

Kinaupenne M, De Craemer M, Schaballie H, Vandekerckhove K, Van Biervliet S, Demeyer H Eur Respir Rev. 2024; 31(165).

PMID: 38743505 PMC: 9724827. DOI: 10.1183/16000617.0010-2022.


One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes.

Castaldo A, Gelzo M, Iacotucci P, Longobardi A, Taccetti G, Terlizzi V Front Mol Biosci. 2024; 10:1327958.

PMID: 38259684 PMC: 10800484. DOI: 10.3389/fmolb.2023.1327958.


Epidemiological Profile of Hospitalized Patients with Cystic Fibrosis in Brazil Due to Severe Acute Respiratory Infection during the COVID-19 Pandemic and a Systematic Review of Worldwide COVID-19 in Those with Cystic Fibrosis.

Marques L, Boschiero M, Sansone N, Brienze L, Marson F Healthcare (Basel). 2023; 11(13).

PMID: 37444770 PMC: 10341451. DOI: 10.3390/healthcare11131936.


Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment.

Carnovale V, Scialo F, Gelzo M, Iacotucci P, Amato F, Zarrilli F J Clin Med. 2022; 11(23).

PMID: 36498475 PMC: 9735556. DOI: 10.3390/jcm11236900.